Information for Legislators About the Insulin Price Crisis

Across the United States, lawmakers have recognized the need for change as their constituents struggle to access and afford their essential medications, especially insulin. The insulin crisis is forcing patients to resort to drastic measures to stay alive. Countless people have to choose between buying their insulin and paying their rent, buying food, or other unthinkable sacrifices.

Insulin is like oxygen for someone with type 1 diabetes, and over 7 million Americans rely on injected insulin to stay alive and healthy.

Patient Voices Matter

It’s important that legislators speak directly with patients. If you haven’t heard from members of your constituency who have been affected by high insulin prices, get in touch with T1International. We can help connect you to patients in your state. You can also try reaching out to them via social media using the #insulin4all hashtag. This is an issue that affects patients and families in every constituency, and hearing from them will be a huge benefit to your policy-making.

Legislative Action

Senators and Representatives have introduced bills at both the federal and state levels to address the drug cost crisis in the United States. From emergency refill legislation to transparency laws and price capping measures, there are a variety of legislative options that may help patients with type 1 diabetes. 

T1International Chapters across the USA are working with their legislators to take action and introduce the types of bills outlined below to address insulin access issues.

The Role of Pharmacy Benefit Managers (PBMs)

We recognize that PBMs and rebates are an important part of the drug pricing issue, and that they share part of the blame when it comes to affordable prescription drug prices. However, we feel strongly that the focus should remain on the root cause of the crisis, which is list prices set by the manufacturers. If we spend too much time and focus on PBMs, patients still suffer and the 90% of the problem - pharmaceutical companies - remains unchecked.